- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01174576
Acute Effects of Coffee on Appetite and Inflammation Markers, Glucose Metabolism and Energy Intake
Acute Effects of Caffeinated and Decaffeinated Coffee Consumption on Energy Intake, Appetite, Inflammation and Glucose Metabolism
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Coffee is a pharmacologically active, widely consumed beverage. Scientific interest in relation to coffee consumption has been revisited the last decade in the light of new, mainly epidemiological, evidence indicating its potential health benefits. In specific, both cross-sectional and prospective studies indicate that coffee consumption is associated with a lower risk for type 2 diabetes. Furthermore, an inverse association has been found between coffee consumption and markers of inflammation and endothelial dysfunction in healthy and/or diabetic participants, although the opposite effect has also been reported, mainly in relation to inflammation markers. In relation to body weight, epidemiological data suggest that increment in caffeine consumption is associated with lower mean weight gain and energy intake during a 12-y period.
However, information from clinical studies is scarce. Acute caffeine and/or coffee consumption have been associated with impaired glucose metabolism and insulin resistance. In relation to inflammation, animal studies have indicated a beneficial or no effect of coffee consumption, whereas a clinical study in humans found an increase in adiponectin and a decrease in interleukin-18 (IL-18) blood concentrations after a monthly intervention including daily consumption of 8 cups of coffee. As far as energy balance is concerned, there is an early experiment demonstrating that the ingestion of 300 mg of caffeine prior to food intake, compared to the non-caffeine intake, significantly reduced energy intake by 21.7% in men, but not in women. A more recent study has found that the combination of caffeine and red pepper is positively associated with energy expenditure and negatively with energy intake, whereas, it has also been reported a positive association between habitual caffeine intake and body weight loss achieved through a very-low-calorie diet.
Taking into consideration the limited clinical evidence regarding the acute effect of coffee consumption on appetite-related markers, subsequent energy intake and inflammatory markers, we undertook a clinical study of crossover design to investigate the short-term changes on energy intake, subjective appetite ratings, appetite hormones, inflammation markers and glucose metabolism after caffeinated and decaffeinated coffee consumption.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Athens, Greece, 17671
- Metabolic Unit of the Department of Nutrition and Dietetics, Harokopio University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- healthy
- non-obese
Exclusion Criteria:
- smokers
- restrained eaters (as this was evaluated using the Dutch Eating Behaviour Questionnaire and a total score > 2.5)
- those who reported slimming or any other dietary regime
- abstainers from caffeine sources
- athletes during competition period
- participants with a known diagnosis of either hypertension, diabetes, impaired glucose tolerance or a fasting blood glucose concentration above 125 mg/dl
- subjects on medication for hypertension or on medication known to alter glucose metabolism
- subjects who were on medication that may have an impact on appetite and sensory functioning or who reported a metabolic or endocrine disease, gastrointestinal disorders, or a history of medical or surgical events that may have affected the study outcomes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: caffeinated coffee
200 mL caffeinated coffee with 3 mg caffeine per kg body weight
|
3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
|
|
Experimental: decaffeinated coffee
200 mL decaffeinated coffee, same amount as caffeinated coffee
|
3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
|
|
Experimental: Water
200 mL, control intervention
|
3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ghrelin Total Area Under the Curve
Time Frame: 15 min before ingestion to 3 hr post ingestion
|
Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule.
The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.
|
15 min before ingestion to 3 hr post ingestion
|
|
Peptide Tyrosine Tyrosine (PYY) Total Area Under the Curve
Time Frame: 15 min before ingestion to 3 hr post ingestion
|
Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule.
The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.
|
15 min before ingestion to 3 hr post ingestion
|
|
Glucagon-like Peptide-1 (GLP-1) Total Area Under the Curve
Time Frame: 15 min before ingestion to 3 hr post ingestion
|
Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule.
The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.
|
15 min before ingestion to 3 hr post ingestion
|
|
Adiponectin Total Area Under the Curve
Time Frame: 15 min before ingestion to 3 h post ingestion
|
Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule.
The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.
|
15 min before ingestion to 3 h post ingestion
|
|
Inteleukin-6 Total Area Under the Curve
Time Frame: 15 min before ingestion to 3 hr post ingestion
|
Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule.
The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.
|
15 min before ingestion to 3 hr post ingestion
|
|
Interleukin-18 Total Area Under the Curve
Time Frame: 15 min before ingestion to 3 hr post ingestion
|
Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule.
The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.
|
15 min before ingestion to 3 hr post ingestion
|
|
Glucose Total Area Under the Curve
Time Frame: 15 min before ingestion to 3 hr post ingestion
|
Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule.
The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.
|
15 min before ingestion to 3 hr post ingestion
|
|
Insulin Total Area Under the Curve
Time Frame: 15 min before ingestion to 3 hr post ingestion
|
Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule.
The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.
|
15 min before ingestion to 3 hr post ingestion
|
|
Cortisol Total Area Under the Curve
Time Frame: 15 min before ingestion to 3 hr post ingestion
|
Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule.
The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.
|
15 min before ingestion to 3 hr post ingestion
|
|
Energy ad Libitum Meal
Time Frame: 3 hr post ingestion
|
The energy of first meal 3 hr after ingestion
|
3 hr post ingestion
|
|
Total Energy Intake
Time Frame: 1 d
|
the energy consumed at breakfast, ad libitum meal and rest of the experimental day
|
1 d
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum Antioxidant Capacity Total Area Under the Curve
Time Frame: 15 min before ingestion to 21/2 hr post ingestion
|
Serum samples, collected 15 min before ingestion, immediately after ingestion, 15 min, 30 min, 60 min, 90 min, 120 min and 150 min after ingestion were analyzed for the ex vivo serum resistance to oxidative stress, that was induced by copper sulfate (CuSO4). The analysis of all collected samples was performed by the measurement of conjugated diene formation, which was monitored for every sample of all time points every 2 min for a 3.5 h period at 234 nm in a microplate spectrophotometer. Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule. The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150 min postconsumption. |
15 min before ingestion to 21/2 hr post ingestion
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Mary Yannakoulia, PhD, Harokopio University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CofSt
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Health
-
BIO-CAT Microbials, LLCBiofortis Clinical Research, Inc.CompletedImmune Health | Cardiovascular Health | Gastrointestinal Health | Digestive HealthUnited States
-
Cambridge Health AllianceNot yet recruitingMental Health | Adolescent Health | Minority Health | Community Health Services
-
Universiti Teknologi MaraUniversiti Putra Malaysia; Ministry of Health, Malaysia; Institute for Health... and other collaboratorsRecruitingHealth Attitude | Health Behavior | Knowledge, Attitudes, Practice | Health Knowledge, Attitudes, Practice | Health-Related Behavior | Behavior, Health | Attitude to Health | Preparedness | OutbreaksMalaysia
-
Ankara Yildirim Beyazıt UniversityNot yet recruitingHealth Attitude | Health Behavior | Health KnowledgeTurkey
-
Nag Food Supplement Trading LLCCitruslabsCompletedSkin Health | Hair Health | Joint HealthUnited States
-
BIO-CAT Microbials, LLCOhio State University; Biofortis Clinical Research, Inc.CompletedImmune Health | Gastrointestinal Health | Digestive HealthUnited States
-
King's College LondonNational Cancer Institute (NCI); Cancer Research UK; French National Cancer Institute... and other collaboratorsNot yet recruitingCancer | Mental Health | Resilience | Other | Allergies | Cardiovascular Health | Cognitive Health | Respiratory Health | Metabolic Health | Eye Health | Ageing Well | Psychological Health | Musculoskeletal Health | Neurological Health | Environmental Health Effects
-
Holbaek SygehusCompletedHealth Behavior | Health Knowledge, Attitudes, Practice | Health-Related Behavior | Health LiteracyDenmark
-
Oregon Health and Science UniversityFederal Emergency Management Agency; National Fallen Firefighters FoundationCompletedHealth Behavior | Occupational Health | Total Worker HealthUnited States
-
VA Office of Research and DevelopmentCompletedMental Health | Veterans Health | Rural HealthUnited States
Clinical Trials on caffeinated and decaffeinated coffee
-
Assistance Publique - Hôpitaux de ParisCompletedADCY5-related DyskinesiaFrance
-
Massachusetts Eye and Ear InfirmaryCompleted
-
National Institute of Diabetes and Digestive and...Beth Israel Deaconess Medical Center; Harvard School of Public Health (HSPH)CompletedOverweightUnited States
-
University College CorkCompleted
-
Marmara UniversityCompletedBody Composition MeasurementTurkey
-
Weill Medical College of Cornell UniversityEnrolling by invitationTerbinafine Adverse ReactionUnited States
-
Cedars-Sinai Medical CenterCompletedPostoperative IleusUnited States
-
KTO Karatay UniversityRecruitingPostoperative Pain | Gastrointestinal Motility | Psychological Well-BeingTurkey (Türkiye)
-
Temple UniversityCompleted